Purespring Therapeutics has become the first company to successfully treat kidney disease models by directly targeting the podocyte – a specialised cell implicated in approximately 60% of renal diseases. The company has developed a proprietary adeno-associated viral (AAV) gene therapy platform, building on the pioneering research by Professor Moin Saleem, Professor of Paediatric Renal Medicine at Bristol Medical School.
Gene therapy — a technique which replaces or alters a faulty gene or adds a new gene to treat or prevent disease instead of using drugs or surgery, offers a potential new type of treatment for renal conditions. Purespring’s platform approach enables streamlined gene therapy development for renal diseases, offering the potential to halt, reverse and even cure both rare and common kidney diseases.